Antibody engineering and therapeutics conference

mAbs

Volumn 5, Issue 6, 2013, Pages 817-825

  Almagro, Juan Carlos ^a   Gilliland, Gary L ^b   Scott, Jamie ^c   Larrick, James W ^d   Plückthun, Andreas ^e   Veldman, Trudi ^f   Adams, Gregory P ^g   Parren, Paul WHI ^h   Chester, Kerry A ⁱ   Bradbury, Andrew ^j   Reichert, Janice M ^k   Huston, James S ^l  

^a PFIZER INC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c SIMON FRASER UNIVERSITY   (Canada)

^d Pharmaceutical Development   (United States)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f ABBVIE INC   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h GENMAB   (Netherlands)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j LOS ALAMOS NATIONAL LABORATORY   (United States)

^k Reichert Biotechnology Consulting LLC   (United States)

^l Huston BioConsulting LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABT 414; BISPECIFIC ANTIBODY; CD20 ANTIBODY; CETUXIMAB; DIGOXIN; EVOLOCUMAB; FC RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLEMBATUMUMAB VEDOTIN; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IRON; LOW DENSITY LIPOPROTEIN RECEPTOR; MARINOBUFAGENIN ANTIBODY; METAL NANOPARTICLE; MONOCLONAL ANTIBODY; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIBODY STRUCTURE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CHRONIC KIDNEY FAILURE; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM DIFFICILE; COMPLEMENT ACTIVATION; COMPLEMENTARITY DETERMINING REGION; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG EFFICACY; EXPERIMENTAL DIABETES MELLITUS; FLUORESCENCE ACTIVATED CELL SORTING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE SEQUENCE; GENETIC VARIABILITY; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOBIOLOGY; IMMUNOGLOBULIN GENE; IMMUNOTHERAPY; INTERNALIZATION; KIDNEY FIBROSIS; LOSS OF FUNCTION MUTATION; MAXIMUM TOLERATED DOSE; MELANOMA; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREECLAMPSIA; PROTEOMICS; PSEUDOMONAS AERUGINOSA; SECONDARY PREVENTION; SYSTEM ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR IMMUNITY; VACCINATION;

EID: 84890106384     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26545     Document Type: Conference Paper

References (0)